We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

HORIBA Medical

HORIBA ABX designs, develops and distributes worldwide, in vitro diagnostic systems for biological analysis in medica... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Horiba Showcases New Generation Automated Hemostasis Analyzers at ISTH 2022

By LabMedica International staff writers
Posted on 07 Jul 2022
Print article
Image: The new generation Yumizen G800 and G1550 hemostasis analyzers (Photo courtesy of Horiba Medical)
Image: The new generation Yumizen G800 and G1550 hemostasis analyzers (Photo courtesy of Horiba Medical)

Horiba Medical (Kyoto, Japan) showcased the latest additions to its Yumizen G range of hemostasis analyzers and reagents at ISTH 2022 Congress - the premier event in the field of thrombosis and hemostasis - at London’s Excel from 9-13 July 2022.

At ISTH 2022, HORIBA introduced its new generation Yumizen G800 and G1550 hemostasis analyzers, as well as new ready-to-use reagents for frequently undertaken blood coagulation tests. With these introductions, HORIBA now offers a complete portfolio of hemostasis systems and an innovative reagent range suitable for all laboratory sizes and requirements. HORIBA’s comprehensive Yumizen G hemostasis product range fully supports high quality and cost-effective screening and assessment of bleeding disorders. The new generation of HORIBA Yumizen G800 and G1550 automated analyzers are designed for managing the coagulation, thrombophilia diagnostics and monitoring requirements of clinical laboratories with mid- to high-workloads. Supporting coagulant nephelometry, immuno-turbidimetric and chromogenic testing, these analyzers offer independent and integrated measurement channels.

The new hemostasis line also includes: liquid reagents for more than 80% of laboratory activity; pre-calibrated tests; continuous sample access and loading; as well as innovative management of reflex and additional tests. For urgent samples, it also offers eight STAT sample positions available at any time. Yumizen G systems use only one cuvette per test to avoid waste and overconsumption. The Yumizen G range has been designed to optimize costs, reduce expenses and reduce impact on environment.

Alongside the Yumizen G hemostasis range, HORIBA presented a variety of new specialty reagent additions, including dRVVT, protein S, protein C and Antithrombin screening and confirmation. HORIBA demonstrated its HELO laboratory automation platforms for hematology. Based on the combination of innovative and proven technologies, the HELO solution is capable of enhancing productivity and efficiency of any type of laboratory. At ISTH 2022, HORIBA also hosted a symposium with key opinion leaders in hemostasis from the UK and France presenting on the latest reagent evaluations and advancements in thrombophilia diagnosis.

“Leveraging our many years of expertise in hematology, we have meticulously designed all our Yumizen G systems to ensure that they are easy-to-use, efficient, robust and safe, along with a continuously expanding repertoire of tests,” said Bruno Pougault, Global Hemostasis Product Manager, HORIBA Medical.

Related Links:
Horiba Medical 

Gold Supplier
Infectious Diseases Controls
Multichem ID-SeroNeg
Gold Supplier
Group A Streptococcus Antigen Test
OSOM Strep A Test
Chlamydia Infection Diagnostic Test
Chlamydia Test
Intact Brentuximab Vedotin “Sandwich” Test
EDI Intact Brentuximab Vedotin ELISA Kit

Print article


Clinical Chem.

view channel
Image: ELISA kit for liver-type fatty acid–binding protein (L-FABP). The level of L-FABP present in urine reflects the level of renal tubular dysfunction (Photo courtesy of Sekisui Medical Co)

Urinary Biomarkers Predict Weaning From Acute Dialysis Therapy

Acute kidney injury is associated with a higher risk of chronic kidney disease (CKD), end-stage renal disease, and long-term adverse cardiovascular effects. Critically ill patients with acute kidney injury... Read more


view channel
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Immune Regulators Predict Severity of Plasmodium vivax Malaria

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules... Read more


view channel
Image: Breast cancer spread uncovered by new molecular microscopy (Photo courtesy of Wellcome Sanger Institute)

New Molecular Microscopy Tool Uncovers Breast Cancer Spread

Breast cancer commonly starts when cells start to grow uncontrollably, often due to mutations in the cells. Overtime the tumor becomes a patchwork of cells, called cancer clones, each with different mutations.... Read more


view channel
Image: With Cell IDx’s acquisition, Leica Biosystems will be moving its multiplexing menu forward (Photo courtesy of Leica Biosystems)

Leica Biosystems Acquires Cell IDx, Expanding Offerings in Multiplexed Tissue Profiling

Leica Biosystems, a technology leader in automated staining and brightfield and fluorescent imaging (Nussloch, Germany), has acquired Cell IDx, Inc. (San Diego, CA, USA), which provides multiplex staining... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.